These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33235140)

  • 1. Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients.
    Graham RT; Bell EH; Webb A; Zhao Y; Timmers C; Fleming JL; Sells BE; Robison NJ; Palmer JD; Finlay JL; Chakravarti A
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1201-e1204. PubMed ID: 33235140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
    Kang SH; Park KJ; Kim CY; Yu MO; Park CK; Park SH; Chung YG
    J Neurooncol; 2011 Feb; 101(3):477-86. PubMed ID: 20556478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and genomic features of gliosarcomas.
    Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH
    J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of O6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: a clinicopathologic and immunohistochemical study of seven cases at a single institution.
    Lin JW; Wu YT; Chang IW
    Indian J Pathol Microbiol; 2011; 54(4):683-7. PubMed ID: 22234090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1.
    Huttner AJ; Kieran MW; Yao X; Cruz L; Ladner J; Quayle K; Goumnerova LC; Irons MB; Ullrich NJ
    Pediatr Blood Cancer; 2010 Jul; 54(7):890-6. PubMed ID: 20310005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas.
    Shi ZF; Li KK; Kwan JSH; Yang RR; Aibaidula A; Tang Q; Bao Y; Mao Y; Chen H; Ng HK
    Brain Pathol; 2019 Nov; 29(6):782-792. PubMed ID: 30861589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
    Pfaff E; Kessler T; Balasubramanian GP; Berberich A; Schrimpf D; Wick A; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Capper D; Schenkel I; Eisenmenger A; Dettmer S; Brors B; Platten M; Pfister SM; von Deimling A; Jones DTW; Wick W; Sahm F
    Neuro Oncol; 2018 May; 20(6):826-837. PubMed ID: 29165638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
    Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
    J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
    Kavouridis VK; Ligon KL; Wen PY; Iorgulescu JB
    J Neurooncol; 2022 May; 158(1):111-116. PubMed ID: 35474499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
    Buttarelli FR; Massimino M; Antonelli M; Lauriola L; Nozza P; Donofrio V; Arcella A; Oliva MA; Di Rocco C; Giangaspero F
    Childs Nerv Syst; 2010 Aug; 26(8):1051-6. PubMed ID: 20552207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT gene promoter methylation in pediatric glioblastomas.
    Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
    Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
    Jakob J; Hille M; Sauer C; Ströbel P; Wenz F; Hohenberger P
    Radiat Oncol; 2012 Oct; 7():180. PubMed ID: 23110891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.